

CTI BIOPHARMA CORP  
Form 8-K  
July 27, 2015

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 27, 2015

CTI BIOPHARMA CORP.

(Exact name of registrant as specified in its charter)

Washington                      001-12465      91-1533912  
(State or other jurisdiction of      (Commission      (I.R.S. Employer

incorporation or organization)      File Number)      Identification Number)

3101 Western Avenue, Suite 600

Seattle, Washington 98121

(Address of principal executive offices)

Registrant's telephone number, including area code: (206) 282-7100

Not applicable

Edgar Filing: CTI BIOPHARMA CORP - Form 8-K

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On July 27, 2015, Bruce J. Seeley became the Company's Executive Vice President and Chief Commercial Officer. In this capacity, Mr. Seeley will oversee the Company's commercial organization worldwide, including sales, marketing, commercial operations, medical affairs and supply chain.

In connection with the transition of medical affairs to the new Chief Commercial Officer, effective July 27, 2015, Dr. Jack Singer assumes the position of Chief Scientific Officer and will continue to serve as Executive Vice President, Interim Chief Medical Officer and Global Head of Translational Medicine. He will also continue to serve on the Company's Board of Directors.

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CTI BIOPHARMA CORP.

Date: July 27, 2015 By: /s/ Louis A. Bianco  
Louis A. Bianco  
Executive Vice President, Finance and  
Administration